State-of-the-art behavioral and pharmacological treatments for alcohol use disorder

References

• Organization WH, Unit WHOMoSA. Global status report on alcohol and health, 2014: World Health Organization, 2014.
   Google Scholar
• Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA psychiatry. 2015;72(8):757–66. doi:10.1001/jamapsychiatry.2015.0584.
   PubMed Web of Science ®Google Scholar
• Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend. 2004;74(3):223–34.
   PubMed Web of Science ®Google Scholar
• Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, et al.. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry. 2017;74(9):911–23. doi:10.1001/jamapsychiatry.2017.2161.
   PubMed Web of Science ®Google Scholar
• Keyes KM, Grant BF, Hasin DS. Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population. Drug Alcohol Depend. 2008;93(1–2):21–29. doi:10.1016/j.drugalcdep.2007.08.017.
   PubMed Web of Science ®Google Scholar
• Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, de Girolamo G, Haro JM, Jin R, et al.. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry. 2009;66(7):785–95. doi:10.1001/archgenpsychiatry.2009.36.
   PubMed Web of Science ®Google Scholar
• Keyes KM, Li G, Hasin DS. Birth cohort effects and gender differences in alcohol epidemiology: a review and synthesis. Alcohol Clin Exp Res. 2011;35(12):2101–12. doi:10.1111/j.1530-0277.2011.01562.x.
   PubMed Web of Science ®Google Scholar
• Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD. 2010 national and state costs of excessive alcohol consumption. Am J Prev Med. 2015;49(5):e73–e79. doi:10.1016/j.amepre.2015.05.031.
   PubMedGoogle Scholar
• Keyes KM, Hatzenbuehler ML, McLaughlin KA, Link B, Olfson M, Grant BF, Hasin D. Stigma and treatment for alcohol disorders in the United States. Am J Epidemiol. 2010;172(12):1364–72. doi:10.1093/aje/kwq304.
   PubMed Web of Science ®Google Scholar
• Yoast RA, Wilford BB, Hayashi SW. Encouraging physicians to screen for and intervene in substance use disorders: obstacles and strategies for change. J Addict Dis. 2008;27(3):77–97. doi:10.1080/10550880802122687.
   PubMed Web of Science ®Google Scholar
• Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: findings from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2007;86(2–3):214–21. doi:10.1016/j.drugalcdep.2006.06.008.
   PubMed Web of Science ®Google Scholar
• Schuler MS, Puttaiah S, Mojtabai R, Crum RM. Perceived barriers to treatment for alcohol problems: A latent class analysis. Psychiatr Serv. 2015;66(11):1221–28. doi:10.1176/appi.ps.201400160.
   PubMed Web of Science ®Google Scholar
• Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(7):830–42. doi:10.1001/archpsyc.64.7.830.
   PubMed Web of Science ®Google Scholar
• Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Mn S, et al.. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addiction Biology. 2013;18(6):937–46. doi:10.1111/adb.12012.
   PubMed Web of Science ®Google Scholar
• Ray LA, Bujarski S, Yardley MM, Roche DJO, Hartwell EE. Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?. Am J Drug Alcohol Abuse. 2017;43(6):703–10. doi:10.1080/00952990.2017.1312423.
   PubMed Web of Science ®Google Scholar
• Rohn MC, Lee MR, Kleuter SB, Schwandt ML, Falk DE, Leggio L. Differences between treatment-seeking and nontreatment-seeking alcohol-dependent research participants: an exploratory analysis. Alcohol Clin Exp Res. 2017;41(2):414–20. doi:10.1111/acer.13304.
   PubMed Web of Science ®Google Scholar
• Weisner C, Matzger H. A prospective study of the factors influencing entry to alcohol and drug treatment. J Behav Health Serv Res. 2002;29(2):126–37. doi:10.1007/BF02287699.
   PubMed Web of Science ®Google Scholar
• Sobell LC, Cunningham JA, Sobell MB. Recovery from alcohol problems with and without treatment: prevalence in two population surveys. Am J Public Health. 1996;86(7):966–72.
   PubMed Web of Science ®Google Scholar
• Mulia N, Karriker-Jaffe KJ, Witbrodt J, Bond J, Williams E, Zemore SE. Racial/ethnic differences in 30-year trajectories of heavy drinking in a nationally representative U.S. Samp Drug Alcohol Depend. 2017;170:133–41. doi:10.1016/j.drugalcdep.2016.10.031.
   PubMed Web of Science ®Google Scholar
• Karlamangla A, Zhou K, Reuben D, Greendale G, Moore A. Longitudinal trajectories of heavy drinking in adults in the United States of America. Addiction. 2006;101(1):91–99. doi:10.1111/j.1360-0443.2005.01299.x.
   PubMed Web of Science ®Google Scholar
• Bischof G, Rumpf HJ, Hapke U, Meyer C, John U. Types of natural recovery from alcohol dependence: a cluster analytic approach. Addiction. 2003;98(12):1737–46.
   PubMed Web of Science ®Google Scholar
• Kaner EF, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, Heather N, Saunders J, Burnand B. Effectiveness of brief alcohol interventions in primary care populations. The Cochrane Data of Syst Rev. 2007;(2):Cd004148.
   PubMed Web of Science ®Google Scholar
• Bertholet N, Daeppen JB, Wietlisbach V, Fleming M, Burnand B. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med. 2005;165(9):986–95. doi:10.1001/archinte.165.9.986.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, Degutis LC. Preventive care in the emergency department: screening and brief intervention for alcohol problems in the emergency department: a systematic review. Acad Emerg Med: Official J Soc Acad Emerg Med. 2002;9(6):627–38.
   PubMed Web of Science ®Google Scholar
• Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction. 2002;97(3):279–92.
   PubMed Web of Science ®Google Scholar
• Substance A, Mental HSAU, General O. Facing addiction in America: the surgeon general’s report on alcohol, drugs, and health. 2016.
   Google Scholar
• Saitz R. Alcohol screening and brief intervention in primary care: absence of evidence for efficacy in people with dependence or very heavy drinking. Drug Alcohol Rev. 2010;29(6):631–40. doi:10.1111/j.1465-3362.2010.00217.x.
   PubMed Web of Science ®Google Scholar
• Riper H, Andersson G, Hunter SB, de Wit J, Berking M, Cuijpers P. Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis. Addiction. 2014;109(3):394–406. doi:10.1111/add.12441.
   PubMed Web of Science ®Google Scholar
• Miller WR, Rollnick S. Motivational interviewing: helping people. (change): Guilford press; 2012.
   Google Scholar
• Schmidt CS, Schulte B, Seo HN, Kuhn S, O’Donnell A, Kriston L, Verthein U, Reimer J. Meta-analysis on the effectiveness of alcohol screening with brief interventions for patients in emergency care settings. Addiction. 2016;111(5):783–94. doi:10.1111/add.13263.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Garbutt JC, Amick HR, Brown JM, Brownley KA, Council CL, Viera AJ, Wilkins TM, Schwartz CJ, Richmond EM, et al.. Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the. US Prevent Serv Task Force Annals Internal Med. 2012;157(9):645–54. doi:10.7326/0003-4819-157-9-201211060-00544.
   PubMed Web of Science ®Google Scholar
• Monti PM Treating alcohol dependence: A coping skills training guide: Guilford Press, 2002. doi:10.1044/1059-0889(2002/er01)
   Google Scholar
• Carroll KM, Kiluk BD. Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again. Psychol Add Behav : J Soc Psychol Addic Behav. 2017;31(8):847–61. doi:10.1037/adb0000311.
   PubMed Web of Science ®Google Scholar
• Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009;70(4):516–27.
   PubMed Web of Science ®Google Scholar
• McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am. 2010;33(3):511–25. doi:10.1016/j.psc.2010.04.012.
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–87. doi:10.1176/appi.ajp.2007.06111851.
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognit Ther Res. 2012;36(5):427–40. doi:10.1007/s10608-012-9476-1.
   PubMed Web of Science ®Google Scholar
• O’Farrell TJ, Fals-Stewart W. Behavioral couples therapy for alcoholism and drug abuse. J Subst Abuse Treat. 2000;18(1):51–54.
   PubMed Web of Science ®Google Scholar
• Powers MB, Vedel E, Emmelkamp PM. Behavioral couples therapy (BCT) for alcohol and drug use disorders: a meta-analysis. Clin Psychol Rev. 2008;28(6):952–62. doi:10.1016/j.cpr.2008.02.002.
   PubMed Web of Science ®Google Scholar
• McCrady BS, Wilson AD, Munoz RE, Fink BC, Fokas K, Borders A. Alcohol-focused behavioral couple therapy. Fam Process. 2016;55(3):443–59. doi:10.1111/famp.12231.
   PubMed Web of Science ®Google Scholar
• Meyers RJ, Roozen HG, Smith JE. The community reinforcement approach: an update of the evidence. Alcohol Res Health: J National Ins Alcohol Abuse Alcohol. 2011;33(4):380–88.
   PubMed Web of Science ®Google Scholar
• Roozen HG, Boulogne JJ, van Tulder MW, van Den Brink W, De Jong CA, Kerkhof AJ. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend. 2004;74(1):1–13. doi:10.1016/j.drugalcdep.2003.12.006.
   PubMed Web of Science ®Google Scholar
• Davis DR, Kurti AN, Skelly JM, Redner R, White TJ, Higgins ST. A review of the literature on contingency management in the treatment of substance use disorders, 2009–2014. Prev Med. 2016;92:36–46. doi:10.1016/j.ypmed.2016.08.008.
   PubMed Web of Science ®Google Scholar
• Fitzsimons H, Tuten M, Borsuk C, Lookatch S, Hanks L. Clinician-delivered contingency management increases engagement and attendance in drug and alcohol treatment. Drug Alcohol Depend. 2015;152:62–67. doi:10.1016/j.drugalcdep.2015.04.021.
   PubMed Web of Science ®Google Scholar
• Dougherty DM, Lake SL, Hill-Kapturczak N, Liang YY, Karns TE, Mullen J, Roache JD. Using contingency management procedures to reduce at-risk drinking in heavy drinkers. Alcoholism-Clinical Exp Res. 2015;39(4):743–51. doi:10.1111/acer.12687.
   PubMed Web of Science ®Google Scholar
• McDonell MG, Leickly E, McPherson S, Skalisky J, Srebnik D, Angelo F, Vilardaga R, Nepom JR, Roll JM, Ries RK, et al.. Trial of ethyl glucuronide-based contingency management for outpatients with co-occurring alcohol use disorders and serious mental illness. Am J Psychiatry. 2017;174(4):370–77. doi:10.1176/appi.ajp.2016.16050627.
   PubMed Web of Science ®Google Scholar
• Conklin CA, Tiffany ST. Applying extinction research and theory to cue-exposure addiction treatments. Addiction. 2002;97(2):155–67.
   PubMed Web of Science ®Google Scholar
• Loeber S, Croissant B, Heinz A, Mann K, Flor H. Cue exposure in the treatment of alcohol dependence: effects on drinking outcome, craving and self-efficacy. British J Clinic Psychol. 2006;45(Pt 4):515–29. doi:10.1348/014466505X82586.
   PubMed Web of Science ®Google Scholar
• Rohsenow DJ, Monti PM, Rubonis AV, Gulliver SB, Colby SM, Binkoff JA, Abrams DB. Cue exposure with coping skills training and communication skills training for alcohol dependence: 6- and 12-month outcomes. Addiction. 2001;96(8):1161–74. doi:10.1080/09652140120060752.
   PubMed Web of Science ®Google Scholar
• Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, et al.. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25(11):1634–47.
   PubMed Web of Science ®Google Scholar
• Vollstadt-Klein S, Loeber S, Kirsch M, Bach P, Richter A, Buhler M, von der Goltz C, Hermann D, Mann K, Kiefer F. Effects of cue-exposure treatment on neural cue reactivity in alcohol dependence: a randomized trial. Biol Psychiatry. 2011;69(11):1060–66. doi:10.1016/j.biopsych.2010.12.016.
   PubMed Web of Science ®Google Scholar
• Kavanagh DJ, Sitharthan G, Young RM, Sitharthan T, Saunders JB, Shockley N, Giannopoulos V. Addition of cue exposure to cognitive-behaviour therapy for alcohol misuse: a randomized trial with dysphoric drinkers. Addiction. 2006;101(8):1106–16. doi:10.1111/j.1360-0443.2006.01488.x.
   PubMed Web of Science ®Google Scholar
• Mellentin AI, Skot L, Nielsen B, Schippers GM, Nielsen AS, Stenager E, Juhl C. Cue exposure therapy for the treatment of alcohol use disorders: A meta-analytic review. Clin Psychol Rev. 2017;57:195–207. doi:10.1016/j.cpr.2017.07.006.
   PubMed Web of Science ®Google Scholar
• Mellentin AI, Stenager E, Nielsen B, Nielsen AS, Yu F, Smarter A. Pathway for delivering cue exposure therapy? The design and development of a smartphone app targeting alcohol use disorder. JMIR mHealth and uHealth. 2017;5(1):e5. doi:10.2196/mhealth.6500.
   PubMed Web of Science ®Google Scholar
• Smith JW, Frawley PJ, Polissar L. 6-month and 12-month abstinence rates in inpatient alcoholics treated with aversion therapy compared with matched inpatients from a treatment registry. Alcoholism-Clinical Exp Res. 1991;15(5):862–70. doi:10.1111/j.1530-0277.1991.tb00614.x.
   PubMed Web of Science ®Google Scholar
• Walitzer KS, Dermen KH, Barrick C. Facilitating involvement in Alcoholics Anonymous during out-patient treatment: a randomized clinical trial. Addiction. 2009;104(3):391–401. doi:10.1111/j.1360-0443.2008.02467.x.
   PubMed Web of Science ®Google Scholar
• Ferri M, Amato L, Davoli M. Alcoholics Anonymous and other 12-step programmes for alcohol dependence. The Cochrane Data of Syst Rev. 2006;(3):Cd005032.
   PubMed Web of Science ®Google Scholar
• Emrick CD, Tonigan JS, Montgomery H, Little L Alcoholics Anonymous: What is currently known? 1993.
   Google Scholar
• Kownacki RJ, Shadish WR. Does alcoholics anonymous work? The results from a meta-analysis of controlled experiments. Subst Use Misuse. 1999;34(13):1897–916. doi:10.3109/10826089909039431.
   PubMed Web of Science ®Google Scholar
• Tonigan JS, Toscova R, Miller WR. Meta-analysis of the literature on alcoholics anonymous: sample and study characteristics moderate findings. J Stud Alcohol. 1996;57(1):65–72.
   PubMed Web of Science ®Google Scholar
• Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. J Addict Dis. 2009;28(2):145–57. doi:10.1080/10550880902772464.
   PubMed Web of Science ®Google Scholar
• Kelly JF, Dow SJ, Yeterian JD, Kahler CW. Can 12-step group participation strengthen and extend the benefits of adolescent addiction treatment? A prospective analysis. Drug Alcohol Depend. 2010;110(1–2):117–25. doi:10.1016/j.drugalcdep.2010.02.019.
   PubMed Web of Science ®Google Scholar
• Kelly JF, Magill M, Stout RL. How do people recover from alcohol dependence? A systematic review of the research on mechanisms of behavior change in alcoholics anonymous. Addict Res Theory. 2009;17(3):236–59. doi:10.1080/16066350902770458.
   Web of Science ®Google Scholar
• Witkiewitz K, Marlatt GA, Walker D. Mindfulness-based relapse prevention for alcohol and substance use disorders. J Cogn Psychother. 2005;19(3):211. doi:10.1891/jcop.2005.19.3.211.
   Google Scholar
• Bowen S, Chawla N, Marlatt G. Mindfulness-based relapse prevention for addictive behaviors. A clinician guide New York. (London): The Guilford press; 2011.
   Google Scholar
• Bowen S, Witkiewitz K, Clifasefi SL, Grow J, Chawla N, Hsu SH, Carroll HA, Harrop E, Collins SE, Lustyk MK, et al.. Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial. JAMA Psychiatry. 2014;71(5):547–56. doi:10.1001/jamapsychiatry.2013.4546.
   PubMed Web of Science ®Google Scholar
• Witkiewitz K, Bowen S, Douglas H, Hsu SH. Mindfulness-based relapse prevention for substance craving. Addict Behav. 2013;38(2):1563–71. doi:10.1016/j.addbeh.2012.04.001.
   PubMed Web of Science ®Google Scholar
• Li W, Howard MO, Garland EL, McGovern P, Lazar M. Mindfulness treatment for substance misuse: A systematic review and meta-analysis. J Subst Abuse Treat. 2017;75:62–96. doi:10.1016/j.jsat.2017.01.008.
   PubMed Web of Science ®Google Scholar
• Bewick BM, Trusler K, Barkham M, Hill AJ, Cahill J, Mulhern B. The effectiveness of web-based interventions designed to decrease alcohol consumption–a systematic review. Prev Med. 2008;47(1):17–26. doi:10.1016/j.ypmed.2008.01.005.
   PubMed Web of Science ®Google Scholar
• Rosa C, Campbell AN, Miele GM, Brunner M, Winstanley EL. Using e-technologies in clinical trials. Contemp Clin Trials. 2015;45(Pt A):41–54. doi:10.1016/j.cct.2015.07.007.
   PubMed Web of Science ®Google Scholar
• Litvin EB, Abrantes AM, Brown RA. Computer and mobile technology-based interventions for substance use disorders: an organizing framework. Addict Behav. 2013;38(3):1747–56. doi:10.1016/j.addbeh.2012.09.003.
   PubMed Web of Science ®Google Scholar
• Donoghue K, Patton R, Phillips T, Deluca P, Drummond C. The effectiveness of screening and brief intervention for reducing levels of alcohol consumption: a systematic review and meta-analysis. J Med Internet Res. 2014;16(6):e142. doi:10.2196/jmir.3193.
   PubMed Web of Science ®Google Scholar
• White A, Kavanagh D, Stallman H, Klein B, Kay-Lambkin F, Proudfoot J, Drennan J, Connor J, Baker A, Hines E, et al.. Online alcohol interventions: a systematic review. J Med Internet Res. 2010;12(5):e62. doi:10.2196/jmir.1587.
   PubMed Web of Science ®Google Scholar
• Scott-Sheldon LA, Carey KB, Elliott JC, Garey L, Carey MP. Efficacy of alcohol interventions for first-year college students: a meta-analytic review of randomized controlled trials. J Consult Clin Psychol. 2014;82(2):177. doi:10.1037/a0035192.
   PubMed Web of Science ®Google Scholar
• Robins L, Newby J, Wilhelm K, Smith J, Fletcher T, Ma T, Finch A, Campbell L, Andrews G. Internet-delivered cognitive behaviour therapy for depression in people with diabetes: study protocol for a randomised controlled trial. BMJ Open Diabetes Res Care. 2015;3(1):e000144. doi:10.1136/bmjdrc-2015-000144.
   PubMed Web of Science ®Google Scholar
• Devine EG, Ryan ML, Falk DE, Fertig JB, Litten RZ. An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder. Contemp Clin Trials. 2016;50:178–85. doi:10.1016/j.cct.2016.08.006.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res. 2015;39(4):579–84. doi:10.1111/acer.12669.
   PubMed Web of Science ®Google Scholar
• Allen J, Anton RF, Babor TF, Carbonari J. Project MATCH secondary a priori hypotheses. Addiction. 1997;92(12):1671.
   PubMed Web of Science ®Google Scholar
• GROUP PMR. Matching patients with alcohol disorders to treatments: clinical implications from project MATCH. J Ment Health. 1998;7(6):589–602. doi:10.1080/09638239817743.
   Google Scholar
• Bujarski S, O’Malley SS, Lunny K, Ray LA. The effects of drinking goal on treatment outcome for alcoholism. J Consult Clin Psychol. 2013;81(1):13–22. doi:10.1037/a0030886.
   PubMed Web of Science ®Google Scholar
• Petrakis IL. A rational approach to the pharmacotherapy of alcohol dependence. J Clin Psychopharmacol. 2006;26(6):S3–S12. doi:10.1097/01.jcp.0000248602.68607.81.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Rabinowitz AR. Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep. 2006;8(5):383–88.
   PubMedGoogle Scholar
• Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl. 2014;75(Suppl 17):79–88.
   PubMedGoogle Scholar
• Mitchell JM, O’Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med. 2012;4(116):116ra116. doi:10.1126/scitranslmed.3002902.
   Web of Science ®Google Scholar
• Nestler EJ. Is there a common molecular pathway for addiction?. Nat Neurosci. 2005;8(11):1445–49. doi:10.1038/nn1578.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49(11):881–87.
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–80.
   PubMed Web of Science ®Google Scholar
• Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069–77. doi:10.1001/archpsyc.64.9.1069.
   PubMed Web of Science ®Google Scholar
• Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004;28(9):1362–70.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacol (Berl). 2002;160(1):19–29. doi:10.1007/s002130100919.
   PubMed Web of Science ®Google Scholar
• Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, Weltman M, Haber P. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. Addiction. 2008;103(6):953–59. doi:10.1111/j.1360-0443.2008.02215.x.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, et al.. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry. 2015;76(2):e207–213. doi:10.4088/JCP.13m08934.
   PubMed Web of Science ®Google Scholar
• Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565–73. doi:10.1080/09652140120080705.
   PubMed Web of Science ®Google Scholar
• Carmen B, Angeles M, Ana M, María AJ. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811–28. doi:10.1111/j.1360-0443.2004.00763.x.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, et al.. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60(1):92–99.
   PubMed Web of Science ®Google Scholar
• Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, et al.. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381–87. doi:10.1097/01.ALC.0000030561.15921.A9.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. Nefazodone Treat Alcohol Depend Placebo-Control Trial Neuropsychopharmacol. 2000;22(5):493–503.
   Google Scholar
• Krystal JH, Cramer J, Krol W, Kirk G, Rosenheck R. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2003;24(345):200113.
   Google Scholar
• Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36(6):544–52.
   PubMed Web of Science ®Google Scholar
• Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag. 2007;3(5):741–49.
   PubMedGoogle Scholar
• Garbutt JC. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial (vol 293, pg 1617, 2005). Jama-J Am Med Assoc. 2005;293(16):1978–1978. doi:10.1001/jama.293.13.1617.
   Web of Science ®Google Scholar
• O’Malley SS, Garbutt JC, Gasfriend DR, Dong QM, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 2007;27(5):507–12. doi:10.1097/jcp.0b013e31814ce50d.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets. 2010;9(1):23–32. doi:10.2174/187152710790966641.
   PubMed Web of Science ®Google Scholar
• Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11–23. doi:10.1177/0269881107078308.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, et al.. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama. 2014;311(18):1889–900. doi:10.1001/jama.2014.3628.
   PubMed Web of Science ®Google Scholar
• Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res. 2002;26(4):586–92.
   PubMed Web of Science ®Google Scholar
• Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med. 2007;1(3):115–25. doi:10.1097/ADM.0b013e318156c26f.
   PubMed Web of Science ®Google Scholar
• Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur J Pharmacol. 1990;176(3):289–96.
   PubMed Web of Science ®Google Scholar
• Davidson M, Shanley B, Wilce P. Increased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study. Brain Res. 1995;674(1):91–96.
   PubMed Web of Science ®Google Scholar
• Vallari RC, Pietruszko R. Human aldehyde dehydrogenase: mechanism of inhibition of disulfiram. Science. 1982;216(4546):637–39.
   PubMed Web of Science ®Google Scholar
• Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, et al.. Disulfiram treatment of alcoholism. Veterans Admin Coop Study Jama. 1986;256(11):1449–55.
   Google Scholar
• Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. Jama. 1999;281(14):1318–25.
   PubMed Web of Science ®Google Scholar
• Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PloS one. 2014;9(2):e87366. doi:10.1371/journal.pone.0087366.
   PubMed Web of Science ®Google Scholar
• Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today?. Addiction. 2004;99(1):21–24.
   PubMed Web of Science ®Google Scholar
• Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451–62. doi:10.1111/j.1360-0443.2006.01555.x.
   PubMed Web of Science ®Google Scholar
• Group TCSR. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcohol Clin Exp Res. 2003;27(7):1123–31. doi:10.1097/01.ALC.0000078020.92938.0B.
   PubMed Web of Science ®Google Scholar
• Group TCSR. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 2003;27(7):1107–22.
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, et al.. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Jama. 2006;295(17):2003–17. doi:10.1001/jama.295.17.2003.
   PubMed Web of Science ®Google Scholar
• Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65(2):135–44. doi:10.1001/archpsyc.65.2.135.
   PubMed Web of Science ®Google Scholar
• Oslin DW, Leong SH, Lynch KG, Berrettini W, O’Brien CP, Gordon AJ, Rukstalis M. Naltrexone vs placebo for the treatment of alcohol dependence a randomized clinical trial. Jama Psychiatry. 2015;72(5):430–37. doi:10.1001/jamapsychiatry.2014.3053.
   PubMed Web of Science ®Google Scholar
• Mann K, Roos CR, Hoffmann S, Nakovics H, Lemenager T, Heinz A, Witkiewitz K. Precision medicine in alcohol dependence: A controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. Neuropsychopharmacol. 2018;43(4):891–99. doi:10.1038/npp.2017.282.
   PubMed Web of Science ®Google Scholar
• Mann K, Vollstadt-Klein S, Reinhard I, Lemenager T, Fauth-Buhler M, Hermann D, Hoffmann S, Zimmermann US, Kiefer F, Heinz A, et al.. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. Alcohol Clin Exp Res. 2014;38(11):2754–62. doi:10.1111/acer.12546.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56(8):719–24.
   PubMed Web of Science ®Google Scholar
• Mann K, Bladstrom A, Torup L, Gual A van den brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706–13. doi:10.1016/j.biopsych.2012.10.020.
   PubMed Web of Science ®Google Scholar
• Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, et al.. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(4):421–28.
   PubMed Web of Science ®Google Scholar
• Mann K, Torup L, Sorensen P, Gual A, Swift R, Walker B. van den Brink W. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2016;26(12):1941–49. doi:10.1016/j.euroneuro.2016.10.008.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, et al.. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277–86. doi:10.1097/ADM.0b013e31829623f4.
   PubMed Web of Science ®Google Scholar
• Falk DE, Castle IJ, Ryan M, Fertig J, Litten RZ. Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis. J Addict Med. 2015;9(4):296–303. doi:10.1097/ADM.0000000000000133.
   PubMed Web of Science ®Google Scholar
• McKee SA, Harrison EL, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66(2):185–90. doi:10.1016/j.biopsych.2009.01.029.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacol (Berl). 2012;223(3):299–306. doi:10.1007/s00213-012-2717-x.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, Bold KW, Petrakis I, Muvvala S, Jatlow P, et al.. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking a randomized clinical trial. Jama Psychiatry. 2018;75(2):129–38. doi:10.1001/jamapsychiatry.2017.3544.
   PubMed Web of Science ®Google Scholar
• Anthony JC, Echeagaray-Wagner F. Epidemiologic analysis of alcohol and tobacco use. Alcohol Res Health. 2000;24(4):201–08.
   PubMedGoogle Scholar
• Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108–13. doi:10.1016/j.coph.2005.11.003.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70–77. doi:10.1001/jamainternmed.2013.11950.
   PubMed Web of Science ®Google Scholar
• Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429–38. doi:10.1111/j.1530-0277.2008.00706.x.
   PubMed Web of Science ®Google Scholar
• Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691–700.
   PubMed Web of Science ®Google Scholar
• Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, Randall PK. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709–17. doi:10.1176/appi.ajp.2011.10101436.
   PubMed Web of Science ®Google Scholar
• Pani PP, Trogu E, Pacini M, Maremmani I. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2010;2.
   Google Scholar
• Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–74. doi:10.1111/add.13324.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677–85. doi:10.1016/S0140-6736(03)13370-3.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, et al.. Topiramate for treating alcohol dependence - A randomized controlled trial. Jama-J Am Med Assoc. 2007;298(14):1641–51. doi:10.1001/jama.298.14.1641.
   PubMed Web of Science ®Google Scholar
• Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, et al.. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015;35(1):34–42. doi:10.1097/JCP.0000000000000246.
   PubMed Web of Science ®Google Scholar
• Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother. 2008;42(10):1475–80. doi:10.1345/aph.1L157.
   PubMed Web of Science ®Google Scholar
• Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol. 2010;30(3):318–22. doi:10.1097/JCP.0b013e3181db38bb.
   PubMed Web of Science ®Google Scholar
• Sarid-Segal O, Knapp CM, Burch W, Richardson MA, Bahtia S, DeQuattro K, Afshar M, Richambault C, Sickels L, Devine E, et al.. The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers. Am J Drug Alcohol Abuse. 2009;35(5):316–19. doi:10.1080/00952990903060150.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37(5):504–08.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849–57. doi:10.1111/j.1530-0277.2010.01273.x.
   PubMed Web of Science ®Google Scholar
• Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 2014;49(6):654–60. doi:10.1093/alcalc/agu062.
   PubMed Web of Science ®Google Scholar
• Rose AK, Jones A Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction (Abingdon, England) 2018.
   Google Scholar
• Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24(5):737–42.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacol (Berl). 2000;149(4):327–44.
   PubMed Web of Science ®Google Scholar
• Caldwell HK, Wersinger SR, Young WS 3rd.. The role of the vasopressin 1b receptor in aggression and other social behaviours. Prog Brain Res. 2008;170:65–72. doi:10.1016/S0079-6123(08)00406-8.
   PubMed Web of Science ®Google Scholar
• Edwards S, Guerrero M, Ghoneim OM, Roberts E, Koob GF. Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addiction Biology. 2012;17(1):76–85. doi:10.1111/j.1369-1600.2010.00291.x.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Colombo G, Carai MA, Ho A, Gessa GL, Kreek MJ. Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. Alcohol Clin Exp Res. 2011;35(10):1876–83. doi:10.1111/j.1530-0277.2011.01532.x.
   PubMed Web of Science ®Google Scholar
• Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, et al.. 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacol. 2017;42(5):1012–23. doi:10.1038/npp.2016.214.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol. 2008;23(5):417–24. doi:10.1002/hup.944.
   PubMed Web of Science ®Google Scholar
• Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(5):532–35.
   PubMed Web of Science ®Google Scholar
• Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci. 2004;29(6):452–57.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, et al.. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(3):406–16. doi:10.1111/j.1530-0277.2011.01649.x.
   PubMed Web of Science ®Google Scholar
• Brown ES, Davila D, Nakamura A, Carmody TJ, Rush AJ, Lo A, Holmes T, Adinoff B, Caetano R, Swann AC, et al.. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res. 2014;38(7):2113–18. doi:10.1111/acer.12445.
   PubMed Web of Science ®Google Scholar
• Zalewska-Kaszubska J, Bajer B, Gorska D, Andrzejczak D, Dyr W, Bienkowski P. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with lamotrigine. Physiol Behav. 2015;139:7–12. doi:10.1016/j.physbeh.2014.11.026.
   PubMed Web of Science ®Google Scholar
• Muller CA, Schafer M, Schneider S, Heimann HM, Hinzpeter A, Volkmar K, Forg A, Heinz A, Hein J. Efficacy and safety of levetiracetam for outpatient alcohol detoxification. Pharmacopsychiatry. 2010;43(5):184–89. doi:10.1055/s-0030-1249098.
   PubMed Web of Science ®Google Scholar
• Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, et al.. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(8):1421–30. doi:10.1111/j.1530-0277.2011.01716.x.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Fertig J, Mattson M, Egli M. Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005;10(2):323–43. doi:10.1517/14728214.10.2.323.
   PubMedGoogle Scholar
• Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75(1):34–56. doi:10.1016/j.bcp.2007.08.005.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20(9):1534–41.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24(7):1041–49.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol. 2011;31(1):22–30. doi:10.1097/JCP.0b013e31820465fa.
   PubMed Web of Science ®Google Scholar
• Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004;56(10):785–92. doi:10.1016/j.biopsych.2004.07.016.
   PubMed Web of Science ®Google Scholar
• Mann K. Pharmacotherapy of alcohol dependence. CNS Drugs. 2004;18(8):485–504.
   PubMed Web of Science ®Google Scholar
• Myrick H, Brady KT, Malcolm R. New developments in the pharmacotherapy of alcohol dependence. The American J Addict. 2001;10(Suppl):3–15. doi:10.1080/10550490150504092.
   Web of Science ®Google Scholar
• Schaffer A, Naranjo CA. Recommended drug treatment strategies for the alcoholic patient. Drugs. 1998;56(4):571–85.
   PubMed Web of Science ®Google Scholar
• Mason BJ. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res. 1996;20(7 Suppl):10a–16a.
   PubMed Web of Science ®Google Scholar
• Meza E, Kranzler HR. Closing the gap between alcoholism research and practice: the case for pharmacotherapy. Psychiatr Serv. 1996;47(9):917–20. doi:10.1176/ps.47.9.917.
   PubMed Web of Science ®Google Scholar
• McCaul ME, Petry NM. The role of psychosocial treatments in pharmacotherapy for alcoholism. The American J Addict. 2003;12(Suppl 1):S41–S52.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Smith RV, Schnoll R, Moustafa A, Greenstreet-Akman E. Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?. Addiction. 2017;112(12):2086–94. doi:10.1111/add.13818.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Falk DE, Ryan ML, Fertig JB. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res. 2016;40(7):1368–79. doi:10.1111/acer.13093.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A. Medications development to treat alcohol dependence: a vision for the next decade. Addiction Biology. 2012;17(3):513–27. doi:10.1111/j.1369-1600.2012.00454.x.
   PubMed Web of Science ®Google Scholar